# Tango Therapeutics (TNGX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/TNGX
## Company Profile
- Ticker: TNGX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 25.58 USD
- Market cap: 3109931613 USD
- Last updated: 2026-08-12
## Business Overview
### Synthetic Lethality Oncology Company
Tango Therapeutics discovers targeted cancer medicines by identifying genetic dependencies created by tumor-suppressor loss.
### Vopimetostat
Vopimetostat is a brain-penetrant, MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers. Development includes monotherapy and combinations intended to deepen responses in RAS-mutant tumors.
### RAS(ON) Combination Strategy
The company is combining vopimetostat with RAS(ON) inhibitors in pancreatic and lung cancers carrying both MTAP deletion and RAS mutations.
### TNG456
TNG456 is a next-generation PRMT5 inhibitor being evaluated in glioblastoma and other MTAP-deleted cancers, extending Tango's synthetic-lethality strategy into tumors where brain penetration is important.
## Why The Stock Is Moving

Following the latest company update, “Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights”, TNGX closed down 4.81% at $26.34 on Aug 11, 2026. The move occurred in the trading session associated with this earnings update.

## Future Catalysts

- Phase 1/2 data for vopimetostat in combination with RAS(ON) inhibitors at the ESMO Congress on October 23–27, 2026.
- Vopimetostat monotherapy data in lung cancer in the second half of 2026.
- Initial clinical data for TNG456 in glioblastoma and other cancers in the second half of 2026.
- Initiation of a Phase 1/2 study of vopimetostat plus ERAS-0015 in the second half of 2026.

## Recent News
- 2026-08-11 11:00 EST — [Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights](https://biopharmsignal.com/news/TNGX/tango-therapeutics-reports-second-quarter-2026-financial-results-and-provides-bu-e21d31fd) — Source: Tango Therapeutics
- 2026-08-06 22:24 EST — [Tango Therapeutics Announces Executive Chair Transition](https://biopharmsignal.com/news/TNGX/tango-therapeutics-announces-executive-chair-transition-f7c96c55) — Source: Tango Therapeutics
- 2026-06-22 20:05 EST — [Tango Therapeutics Appoints Robert Azelby to Board of Directors](https://biopharmsignal.com/news/TNGX/tango-therapeutics-appoints-robert-azelby-to-board-of-directors-5950b38e) — Source: Tango Therapeutics
- 2026-06-10 02:50 EST — [Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering](https://biopharmsignal.com/news/TNGX/tango-therapeutics-announces-pricing-of-600-million-upsized-public-offering-2335552e) — Source: Tango Therapeutics
- 2026-06-08 20:01 EST — [Tango Therapeutics Announces Proposed $500 Million Public Offering](https://biopharmsignal.com/news/TNGX/tango-therapeutics-announces-proposed-500-million-public-offering-e7a83d9c) — Source: Tango Therapeutics